---
layout: minimal-medicine
title: Caplacizumab
---

# Caplacizumab
### Generic Name
Caplacizumab

### Usage
Caplacizumab is a medication used in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).  It's crucial to understand that Caplacizumab is not a standalone treatment. It's always used *in combination* with plasma exchange and immunosuppressive therapy.  aTTP is a rare and life-threatening blood disorder characterized by the formation of blood clots in small blood vessels, leading to a dangerously low platelet count (thrombocytopenia) and damage to various organs. Caplacizumab helps manage this condition by targeting a specific part of the von Willebrand factor (vWF) protein, a key player in the abnormal clotting process of aTTP.  It does *not* treat other forms of thrombotic thrombocytopenic purpura (TTP).

### Dosage

**Acquired Thrombotic Thrombocytopenic Purpura (aTTP):**

* **Adults:** Caplacizumab is administered intravenously (IV) and subcutaneously (SubQ).  The initial dose (11 mg) is given intravenously at least 15 minutes before the first plasma exchange. Following this, an 11 mg subcutaneous dose is given after the plasma exchange on day 1.  Subsequently, during the daily plasma exchange period, a daily 11 mg subcutaneous dose is administered *after* each plasma exchange. After the plasma exchange period concludes,  11 mg subcutaneously is administered daily for 30 days.  If the underlying disease persists (indicated by suppressed ADAMTS13 activity), treatment may be extended for up to a maximum of 28 additional days.
* **Children:** The safety and effectiveness of Caplacizumab in pediatric patients have not been established.  It should not be used in children.

**Dosage Adjustments:**  No specific dosage adjustments are recommended for hepatic or renal impairment based on current manufacturer labeling. However, caution is advised in patients with severe hepatic impairment, requiring close monitoring for bleeding. For patients with renal impairment (CrCl 15-90 mL/min), no clinically meaningful impact on Caplacizumab pharmacokinetics has been observed.

**Toxicity Management:** If clinically significant bleeding occurs, treatment should be immediately interrupted.  If rapid hemostasis is necessary, von Willebrand factor concentrate may be administered. Close monitoring is required if Caplacizumab treatment is resumed.

### Side Effects

**Common Side Effects (occurring in more than 10% of patients):**

* Headache
* Fatigue
* Paresthesia (numbness or tingling)
* Gingival hemorrhage (bleeding gums)
* Urticaria (hives)
* Bleeding complications (this is a serious side effect and requires immediate medical attention)
* Epistaxis (nosebleeds)
* Fever

**Less Common but Serious Side Effects (occurring in 1-10% of patients):**

* Subarachnoid hemorrhage (bleeding in the space surrounding the brain)
* Injection-site pruritus (itching)
* Urinary tract infection
* Vaginal hemorrhage
* Hematuria (blood in the urine)
* Heavy menstrual bleeding
* Intermenstrual bleeding
* Antibody development
* Bleeding at injection site or catheter site
* Back pain
* Myalgia (muscle pain)
* Dyspnea (shortness of breath)
* Rectal hemorrhage
* Hematoma (bruising)
* Upper gastrointestinal hemorrhage


**Important Note:** This is not an exhaustive list. If you experience any adverse effects, even those not listed here, consult your healthcare provider immediately.

### How it Works

Caplacizumab is a type of antibody fragment that specifically targets the A1-domain of von Willebrand factor (vWF).  vWF is a protein crucial for blood clotting. In aTTP,  vWF is abnormally active, causing excessive platelet adhesion and the formation of harmful blood clots. Caplacizumab works by inhibiting the interaction between vWF and platelets, reducing both vWF-mediated platelet adhesion and the consumption of platelets.  This helps restore normal blood flow and prevent further clot formation.

### Precautions

* **Contraindications:** Caplacizumab is contraindicated in patients with severe known hypersensitivity (e.g., urticaria) to Caplacizumab or any of its components.
* **Increased Risk of Bleeding:**  Caplacizumab increases the risk of bleeding.  Patients should be closely monitored for signs and symptoms of bleeding, particularly those with severe hepatic impairment or those taking other medications that affect hemostasis and coagulation.
* **Use with Caution:**  Use caution in patients with severe acute or chronic hepatic impairment.
* **Pregnancy and Breastfeeding:** Caplacizumab is categorized as Pregnancy Category B1. While there's no direct evidence of harm, there's a risk of bleeding, necessitating close monitoring of both the mother and the newborn.  It's unknown whether Caplacizumab is excreted in breast milk, requiring careful consideration of the risks and benefits before breastfeeding during treatment.
* **Surgery and Invasive Procedures:**  Discontinue Caplacizumab treatment 7 days before any elective surgery, dental procedures, or other invasive interventions.
* **Drug Interactions:** Caplacizumab may enhance the anticoagulant effects of other anticoagulant medications.


### FAQs

* **Q: How is Caplacizumab administered?**  A: The first dose is given intravenously, followed by subcutaneous injections.  Always follow the healthcare provider's instructions for administration.

* **Q: What should I do if I miss a dose?** A: If a dose is missed during the plasma exchange period, take it as soon as possible. If missed after the plasma exchange period, take it within 12 hours.  If more than 12 hours have passed, skip the missed dose and resume the regular schedule.

* **Q: What should I do if I experience bleeding?** A: Stop taking Caplacizumab and immediately contact your doctor or go to the nearest emergency room.

* **Q: Can I take Caplacizumab with other medications?** A:  Inform your doctor of all medications you are currently taking, including over-the-counter drugs and supplements.  Some medications may interact with Caplacizumab.

* **Q: How should I store Caplacizumab?** A: Follow the storage instructions provided by your pharmacist or healthcare provider.


**Disclaimer:** This information is for general knowledge and does not constitute medical advice. Always consult with a healthcare professional for diagnosis, treatment, and any questions regarding your specific medical condition.  This information is based on available data and may be subject to change.  Always refer to the most current prescribing information for the most up-to-date details.
